Big Pharma M&As: Clinical Trial Data Visualization
This interactive data visualization app offers an immersive insights into the
consequences of some of the biggest mergers and acquisitions (M&As) in the pharmaceutical industry.
Users can explore the impact of M&As on pharma companies, by examining how it
affects their number of ran clinical trials, R&D spending, and share prices.
Through this app, users can gain valuable insights into how M&As shape the industry, which can enable them to make informed strategic decisions based on data-driven analysis.
consequences of some of the biggest mergers and acquisitions (M&As) in the pharmaceutical industry.
Users can explore the impact of M&As on pharma companies, by examining how it
affects their number of ran clinical trials, R&D spending, and share prices.
Through this app, users can gain valuable insights into how M&As shape the industry, which can enable them to make informed strategic decisions based on data-driven analysis.
Absolute number of clinical trials ran by companies before and after M&A event (includes stock price of an acquirer)
In 2015 AbbVie acquired PharmacyclicsIn 2020 AbbVie acquired Allergan
Absolute number of clinical trials ran by companies before and after M&A event (includes R&D spending of an acquirer)
In 2015 AbbVie acquired PharmacyclicsIn 2020 AbbVie acquired Allergan
Relative number of clinical trials ran by companies before and after M&A event
*year 0 represents the M&A event of each acquisition